If you’ve watched sports, listened to a podcast, or scrolled a men’s health ad in the past two years, you’ve been marketed testosterone. “Low T” clinics are opening in strip malls and on telehealth apps at a pace that outstrips almost every other corner of the longevity industry, testosterone prescriptions have risen sharply on both sides of the Atlantic, and — this week — the FDA moved to strip the boxed cardiovascular warning off testosterone products and loosen who it can be prescribed to. If that timing feels familiar, it should: this is close to the second time in fifteen years the same drug has gone through the same cycle of aggressive marketing, prescribing boom, and regulatory reckoning.
This article is the version of that story with citations attached to every claim. We look at what TRT actually does, for whom, according to the trial data and guideline bodies — not according to a clinic’s landing page.
Key takeaways
- The FDA moved in July 2026 to remove testosterone’s 2015 boxed cardiovascular warning and to allow prescribing for age-related symptoms like low libido, not just confirmed pathological hypogonadism — a major, very recent policy shift.
- The largest cardiovascular safety trial to date, TRAVERSE (5,246 men, NEJM 2023), found TRT did not increase heart attack or stroke risk — but did find more atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group.
- Major guideline bodies disagree on what testosterone level even counts as “low,” with thresholds ranging from 200 to 300 ng/dL depending on the organization — a real, unresolved gap that private clinics have room to exploit.
- A 2026 University of Michigan study found only 12% of men newly started on testosterone at an academic medical center met basic guideline-concordant diagnostic criteria before being prescribed.
- This is not the first “Low T” boom. A similar marketing-driven surge in the 2010s drove testosterone sales past $9.7 billion before the FDA intervened in 2015 — the same warning being removed this year.
What TRT Actually Is, and What It Isn’t
Testosterone replacement therapy is exactly what it sounds like: exogenous testosterone, delivered by injection, gel, patch, or subcutaneous pellet, given to restore levels in men whose bodies aren’t producing enough on their own. It is FDA-approved to treat confirmed hypogonadism — a specific medical condition, not a symptom checklist.
The diagnostic bar, on paper, is consistent across every major guideline body: two separate morning blood tests showing low total testosterone, plus real, corresponding symptoms (low libido, erectile dysfunction, reduced muscle mass, fatigue). Where the guidelines disagree — and this matters more than it should — is on the exact number that counts as “low”:
| Guideline body | Total testosterone threshold |
|---|---|
| American Association of Clinical Endocrinologists | 200 ng/dL |
| International Society of Andrology | 230 ng/dL |
| Endocrine Society | ~264 ng/dL |
| American Urological Association | 300 ng/dL |
That’s not a rounding error — it’s a 50% spread between the most and least conservative guideline thresholds, all from credible, mainstream medical organizations. A private clinic that wants to diagnose more men with “low T” doesn’t need to lie or fabricate anything; it just needs to quietly adopt the more permissive number, or skip the second confirmatory test, or lean on a symptom questionnaire that almost any tired, stressed adult would score positively on. Professor Channa Jayasena of Imperial College London, describing this pattern among UK private clinics in an interview with The Pharmaceutical Journal, has called it “moving the goalposts” — using a more liberal reference range and dosing above what national guidelines recommend.
The 2026 Policy Shift, in Plain Terms
This is genuinely new, and it’s the reason “is TRT worth it” searches are spiking right now. In July 2026, the FDA moved to remove the boxed warning about cardiovascular risk that testosterone products have carried since 2015, and separately proposed rewriting prescribing guidance to permit testosterone for age-related symptoms — low libido, erectile dysfunction — rather than restricting it to men with a confirmed, pathological cause of low testosterone. Health Secretary Robert F. Kennedy Jr. has backed the change, and Defense Secretary Pete Hegseth announced the military will begin screening for low testosterone and offering hormone therapy.
The stated scientific basis is real, not invented: a 2023 FDA-mandated cardiovascular safety study (TRAVERSE, covered in detail below) found no increased heart attack or stroke risk over two years, and separate NIH-funded trials in older men found testosterone improved erectile function and libido, with smaller effects on mood. But the researchers behind that same safety data are notably more cautious than the policy announcement. Dr. Shalender Bhasin, a co-investigator on TRAVERSE and one of the field’s most cited researchers, put it directly: “There’s a lot more to be done to better define the safety and efficacy.” That’s a meaningfully more hedged statement than “the FDA says it’s safe” — and it’s worth sitting with, because it’s coming from someone who ran the actual trial the policy change leans on.
What the Trial Data Actually Shows
The cardiovascular question: TRAVERSE
TRAVERSE is the trial nearly every 2026 headline about testosterone safety is quietly leaning on, so it’s worth understanding what it actually tested. It was a multicenter, randomized, double-blind, placebo-controlled noninferiority trial of 5,246 men aged 45 to 80 with confirmed hypogonadism (testosterone below 300 ng/dL) and either existing cardiovascular disease or multiple risk factors for it — a population selected specifically because it was considered highest-risk for testosterone-related cardiac harm. Participants received daily transdermal testosterone gel or placebo and were followed for a mean of 22 months. The trial, led by researcher A. Michael Lincoff, was published in the New England Journal of Medicine in 2023.
| Outcome | Testosterone group | Placebo group | Result |
|---|---|---|---|
| Major adverse cardiac event (primary endpoint) | 7.0% (182 men) | 7.3% (190 men) | Noninferior (HR 0.96, 95% CI 0.78–1.17) |
| Atrial fibrillation | 91 men | 63 men | More common with testosterone |
| Acute kidney injury | Higher | — | More common with testosterone |
| Pulmonary embolism | Higher | — | More common with testosterone |
The headline result is genuinely reassuring: testosterone therapy, in this specific high-risk, guideline-confirmed hypogonadal population, did not increase heart attacks, strokes, or cardiovascular death. That’s a real, well-designed, FDA-mandated finding, and it’s the correct scientific basis for softening blanket cardiovascular alarm. But the secondary findings are just as real: more atrial fibrillation, more acute kidney injury, and more pulmonary embolism in the testosterone group — signals that a subsequent meta-analysis of 106 placebo-controlled trials found were not statistically significant when pooled across the wider literature, but that TRAVERSE itself, as the largest and most rigorous single trial, did detect, according to a 2026 position statement from the European Expert Panel for Testosterone Research. Both of those things are true about the same trial. A policy announcement that cites only the first half is telling you something true and incomplete at the same time.
Before spending money on a "Low T" panel, see what's actually guideline-backed for your age and risk profile. Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →
What TRT does and doesn’t do for symptoms
For men with confirmed, lab-diagnosed hypogonadism, the evidence for specific benefits is real: NIH-funded testosterone trials in older men found meaningful improvement in erectile function and libido, with smaller, more mixed effects on mood, and — notably — limited improvement in fatigue, memory, or general well-being, per the NIH-funded T-Trials research. That last part rarely makes it into a clinic’s marketing copy, where “low energy” and “brain fog” are often the lead symptoms used to sell a consultation.
Evidence grade by claim, not by “TRT” as a monolith:
- Improves libido and erectile function in men with confirmed hypogonadism: Grade A — supported by multiple RCTs and endorsed by AUA and Endocrine Society guidelines.
- Cardiovascular-neutral for major adverse cardiac events in guideline-confirmed hypogonadal men: Grade B — the largest trial met its primary safety endpoint, but real secondary signals (atrial fibrillation, kidney injury, clotting) mean “safe” is not an unqualified conclusion.
- Improves energy, mood, cognition, or general “vitality” in men with normal-to-borderline testosterone: Grade C — the specific claim most TRT clinic marketing leans on hardest has the weakest trial support of the bunch.
- A symptom checklist alone is a reliable basis for a TRT diagnosis: Grade C — every major guideline requires lab-confirmed low testosterone on two occasions, not symptoms in isolation.
Is TRT Actually Overprescribed?
This is where the marketing-versus-medicine gap gets measurable, not just anecdotal.
At ENDO 2026 in Chicago, researchers from the University of Michigan (Sinha and Papaleontiou) presented a retrospective chart review of 200 men newly started on testosterone therapy at an academic primary care network between 2020 and 2025. The finding: only 12% met basic guideline-concordant diagnostic criteria — two low morning testosterone readings, measured LH/FSH, and no contraindications — before being prescribed. PSA had been checked in only 62% of patients and a complete blood count in 77%, both standard pre-treatment safety checks under AUA guidance. This was a single academic health system, not a national sample, and it’s a conference-presented finding rather than a peer-reviewed published paper as of this writing — but it’s a rare, direct, chart-level look at how far real-world prescribing has drifted from the guidelines on paper, and it lines up with what’s being reported elsewhere.
In the U.K., a 2025 study of 973 men, reported by The Pharmaceutical Journal, found that 49% reported symptoms commonly associated with low testosterone, while only 5% had ever received a formal diagnosis — an enormous gap between how common “low T” symptoms feel and how rare an actual guideline-confirmed diagnosis is. NHS testosterone prescriptions rose 52% between 2020/21 and 2024/25 over the same period. Neither of those numbers proves fraud or bad intent at the clinic level — some of that gap is simply more men now discussing symptoms they’d have stayed quiet about a decade ago. But taken together with the Michigan chart review, it’s a genuine, data-backed pattern: a rising share of testosterone prescriptions are not clearly meeting the diagnostic bar the drug was approved against.
Why “Low T” Sells: The Psychology, and the Precedent
None of this is really about men being gullible, and it’s worth naming honestly why the pitch works so well.
Fatigue, low libido, and reduced motivation are close to universal experiences, especially for men in their 40s and 50s juggling work, sleep debt, and stress. A symptom list built from those experiences will feel true to almost anyone who reads it — which is exactly what makes it a poor diagnostic tool and an excellent marketing tool at the same time. Feeling seen by a list of symptoms is not the same as having a lab-confirmed hormone deficiency, but the emotional experience of recognition is identical either way.
A single number promises legibility for a vague problem. “Your testosterone is a 280” is a much more satisfying, actionable-feeling answer than “you’re stressed, under-slept, and out of shape,” even when the second explanation is more likely to be true and more directly fixable. That’s the same psychological pull behind biological-age tests and whole-body MRI scans — a number feels like certainty, even when the number’s clinical meaning is contested.
This isn’t the industry’s first attempt at this playbook. Starting in 2007, Abbott Laboratories’ “Is It Low-T?” campaign helped drive a roughly tenfold increase in testosterone prescriptions and pushed annual sales above $2 billion, eventually totaling an estimated $9.7 billion in sales and more than 25 million prescriptions before the FDA intervened in 2015 — specifically because it found testosterone was “being used extensively in attempts to relieve symptoms in men who have low testosterone for no apparent reason other than aging,” with benefits and safety in that population unestablished, as reported at the time by Forbes and The Washington Post. The boxed cardiovascular warning added that year is the same warning the FDA is removing in 2026. Whether the current prescribing boom repeats the last one’s overreach, or whether the TRAVERSE data genuinely justifies a course correction, is the open question this article can’t answer for you — but the pattern is close enough to recent history that it’s worth knowing before you book a consultation.
The Real Risks, Stated Plainly
- Polycythemia (thickened blood). TRT reliably raises red blood cell counts. The AUA guideline gives this a Grade A recommendation: clinicians should check hematocrit before starting treatment and monitor it throughout, withholding or adjusting therapy if it climbs into a range that raises clotting risk.
- Fertility suppression. Exogenous testosterone shuts down the body’s own sperm production in most men. Anyone planning to have children should discuss this with a physician before starting, not after.
- Cardiovascular signals that TRAVERSE didn’t fully resolve. No increased heart attack or stroke risk in the trial population — but more atrial fibrillation, kidney injury, and pulmonary embolism, in a population that was already at elevated cardiovascular risk to begin with.
- Prostate monitoring. PSA should be checked before starting therapy in men over 40 to rule out undiagnosed prostate cancer, and monitored on a normal schedule afterward.
- Illicit and unsupervised use. A growing share of especially younger men are obtaining testosterone outside any clinical relationship, through social media and unregulated suppliers, with no lab monitoring, dose confirmation, or product-quality assurance at all.
Cost Reality
Direct-to-consumer telehealth TRT is a genuinely competitive market, and pricing is more transparent than most of the longevity industry — but the sticker price is rarely the whole bill.
- Typical monthly range: $99 to $300 per month for medication, cash-pay, not covered by insurance, since this is elective self-pay treatment in nearly all cases.
- What’s usually included: Initial consultation and baseline labs, the prescription itself, and some level of follow-up. Exactly what’s bundled varies enormously by provider — some quote an all-inclusive flat monthly rate; others bill labs, follow-up consults, and ancillary medications (like fertility-preserving add-ons) separately.
- Realistic annual cost: A full year of TRT with quarterly lab monitoring, done at a reasonably rigorous clinic, commonly runs $2,400 to $5,400, before any additional peptides or adjunct medications some clinics upsell alongside the core prescription.
- The £20-to-£2,000 pattern in the U.K. mirrors the U.S. market: an initial test can be marketed for under £20, while a full year of private treatment and monitoring runs closer to £2,000.
None of this is inherently predatory — a transparent monthly subscription for a real, guideline-supported treatment is a reasonable business model. The risk is specifically in how easy the on-ramp is: a low-cost initial test, a broad symptom questionnaire, and a same-week prescription, with the more rigorous parts of the guideline (a second confirmatory morning test, LH/FSH, a documented contraindication check) sometimes quietly skipped in the process.
Who Should Actually Consider Getting Tested
We’re not going to tell you whether to get your testosterone checked or start therapy — that’s a conversation for you and a physician who knows your full history. What we can offer are the questions worth asking before you do.
- Have I had two separate morning testosterone tests, or is a prescription being offered off a single reading — or no lab test at all?
- Was LH and FSH measured, which helps distinguish a primary testicular problem from something else entirely (like sleep apnea, obesity, or a pituitary issue) that might be a better explanation for my symptoms?
- Was my hematocrit and PSA checked before starting, and is there a plan to monitor both while I’m on treatment?
- Am I being diagnosed against a specific number, and do I know which guideline’s threshold that number is based on?
- Would this clinic’s diagnosis hold up at a mainstream endocrinology or urology practice, or is it built on a more permissive reference range than most guideline bodies use?
- If I’m planning to have children, has fertility suppression been discussed as part of this decision?
The Bottom Line
Testosterone replacement therapy is a real, guideline-supported treatment for a real, definable medical condition — and the 2026 regulatory shift is grounded in genuine trial data, not pure marketing. At the same time, the diagnostic bar for that condition is being applied inconsistently across the industry, guideline bodies themselves disagree by up to 50% on the defining threshold, and a 2026 chart review found the large majority of men started on TRT at one academic health system didn’t clearly meet the diagnostic standard before treatment began. Both facts are true simultaneously, and the honest answer to “should I get TRT” depends entirely on which side of that gap you’re standing on — something only an actual lab-confirmed diagnosis, not a symptom quiz, can tell you.
Frequently Asked Questions
What is TRT and who is it actually for?
TRT (testosterone replacement therapy) is medication — gels, injections, patches, or pellets — that restores testosterone in men with clinically confirmed hypogonadism: low blood testosterone on two separate morning tests plus real symptoms. It is not, according to any major guideline body, a general treatment for aging, low energy, or mood in men whose testosterone is within a normal range.
Is testosterone replacement therapy safe?
For the population studied in the largest trial to date (TRAVERSE, 5,246 men with confirmed hypogonadism and heart disease or risk factors), TRT did not increase the risk of heart attack, stroke, or cardiovascular death over about two years. The same trial found more atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, and separately carries well-documented risks of polycythemia (thickened blood) and fertility suppression. Safety data for men taking it without confirmed hypogonadism, at higher-than-guideline doses, or for many years is much thinner.
What testosterone level counts as “low”?
It depends who you ask — a genuine, unresolved problem in this field. The American Urological Association uses 300 ng/dL, the Endocrine Society suggests around 264 ng/dL, and the American Association of Clinical Endocrinologists uses 200 ng/dL. Every major guideline agrees a diagnosis requires two separate low morning readings plus symptoms — not one test, one clinic visit, and a prescription.
How much does TRT cost?
Direct-to-consumer telehealth TRT clinics in the U.S. typically charge $99 to $300 per month (roughly $1,200 to $3,600 a year), cash-pay, not covered by insurance. Some providers bundle labs and consultations into that price; others bill them separately, which can push a full year’s cost toward $5,000 or more once peptides or additional medications are added.
Is TRT overprescribed?
Recent research suggests so. A 2026 University of Michigan study presented at the Endocrine Society’s ENDO meeting found that only 12% of men newly started on testosterone therapy at an academic primary care network met basic guideline-concordant diagnostic criteria. A separate 2025 UK study found that while 49% of men reported symptoms associated with low testosterone, only 5% had an actual formal diagnosis — a large gap between how the condition is marketed and how it’s supposed to be diagnosed.
Did the FDA change its rules on testosterone in 2026?
Yes. In July 2026, the FDA moved to remove its 2015 boxed cardiovascular warning from testosterone products and proposed broadening approved use beyond confirmed pathological hypogonadism to include age-related symptoms like low libido and erectile dysfunction. The change followed the 2023 TRAVERSE trial’s cardiovascular-safety findings, though some researchers caution that questions about long-term safety and appropriate patient selection remain open.
Can TRT improve energy, mood, or muscle mass in men with normal testosterone?
The evidence for this specific use is thin. Large NIH-funded trials in older men with age-related low testosterone found meaningful improvements in sexual function and modest mood benefits, but limited effect on fatigue, memory, or general well-being. No major guideline recommends testosterone therapy as a general energy or anti-aging treatment for men with normal-range levels.
This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. Testosterone is a prescription medication with real risks, contraindications, and drug interactions — do not start, stop, or change any medication based on this article. Always consult a clinician before making decisions about screening, testing, or your health.
Sources
- Lincoff AM, Bhasin S, Flevaris P, et al., for the TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine, 2023;389:107–117.
- Zitzmann M, et al. Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research. Andrology, 2026.
- American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline, 2018.
- Endocrine Society. Testosterone Therapy in Men with Androgen Deficiency Syndromes: Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.
- Sinha S, Papaleontiou M. Testosterone Prescribing Practices in Primary Care. Presented at ENDO 2026, Endocrine Society Annual Meeting, Chicago, June 13, 2026. Press release.
- Moore A. Moving the goalposts: the worrying rise of testosterone replacement therapy. The Pharmaceutical Journal, April 30, 2026.
- News4Jax. Trump officials want to make testosterone drugs easier to prescribe. Is that a good idea?, July 16, 2026.
- U.S. Food and Drug Administration. Testosterone product labeling and 2015 safety communication on age-related use, referenced in 2026 regulatory reporting.
- Weintraub A. Why All Those Testosterone Ads Constitute Disease Mongering. Forbes, 2015.
- Sell a disease to sell a drug. The Washington Post, 2015.